23:26 , Jun 28, 2019 |  BC Extra  |  Preclinical News

OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

By partnering with a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec is expanding into CAR T cell therapies for solid tumors. The deal highlights how manufacturing-savvy academic...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
21:17 , Dec 14, 2018 |  BC Week In Review  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he...
20:23 , Dec 10, 2018 |  BC Extra  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he...
17:49 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Seidenberg, Harper launch Westlake with $320M inaugural fund

Kleiner Perkins’ Beth Seidenberg launched a life science investment firm, dubbed Westlake Village BioPartners, with $320 million in committed capital for its first fund. Sean Harper, EVP and head of R&D at Amgen Inc. (NASDAQ:AMGN),...
23:30 , Sep 5, 2018 |  BC Extra  |  Financial News

Seidenberg, Harper launch Westlake with $320M inaugural fund

Kleiner Perkins’ Beth Seidenberg launched a life science investment firm Wednesday, dubbed Westlake Village BioPartners, with $320 million in committed capital for its first fund. Sean Harper, EVP and head of R&D at Amgen Inc....
21:53 , Apr 13, 2018 |  BioCentury  |  Product Development

Self-driving CARs

Novartis AG, Gilead Sciences Inc. and now Pfizer Inc. have taken different approaches to managing their CAR T cell assets, but the three companies appear to be converging on the notion that developing the technology...
12:33 , Feb 27, 2018 |  BC Innovations  |  Emerging Company Profile

Synth supergroup

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes...
21:05 , Dec 8, 2017 |  BC Week In Review  |  Company News

Gilead acquiring synthetic CAR T company Cell Design

On Dec. 7, Gilead Sciences Inc. (NASDAQ:GILD) said it will acquire Cell Design Labs Inc. (San Francisco, Calif.) for $175 million up front, plus up to $322 million in milestones payable to Cell Design’s shareholders....
01:07 , Dec 8, 2017 |  BC Extra  |  Company News

Gilead acquiring synthetic CAR T company Cell Design

Gilead Sciences Inc. (NASDAQ:GILD) will acquire Cell Design Labs Inc. (San Francisco, Calif.) for $175 million up front, plus up to $322 million in milestones payable to Cell Design’s shareholders. Cell Design President and CEO...